SREBF1 and steatosis: Taken together, our results firstly revealed that dapagliflozin treatment relieved steatosis and reduced the expression levels of enzymes involved in DNL by upregulating FXR/SHP and downregulating LXRα/SREBP-1c and inhibiting glucose output in the liver of db/db mice.